In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
Fishway hooks Multus to jointly accelerate cultivated fish
In the United Kingdom, Fishway and Multus Biotechnology have partnered to bring cultivated fish to market faster.
The pact will leverage Fishway's expertise in...
Pirelli unveils biobased tires for Range Rovers
In Milan, tire manufacturer Pirelli has launched the first standard production tire for the global market made with over 70% biobased and recycled materials,...
MIT students design 3D printer that converts home food waste into knick-knacks
In Boston, Massachusetts Institute of Technology students Biru Cao and Qiqing Wang have developed an AI-drive desktop 3D printer that converts household food waste...